A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Clinical Trials Arena on MSN
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...
Pharmaceutical Technology on MSN
Pfizer sets sights on R&D strategy amid modest FY25 results
As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.
Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
Last month, during Cannes Lions, Netflix announced that its ad inventory will be available to buy programmatically via Yahoo DSP. This expansion of Netflix’s programmatic offerings couldn’t come at a ...
Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results